Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Colorado, Denver
Age
18–65
Sex
FEMALE
Healthy volunteers
Accepted
You may not be if
Seated resting blood pressure \>140/90 mmHg
Use of medications that might influence cardiovascular function or cerebral blood flow;
Pregnant, currently breastfeeding or intention to become pregnant in the next 6 months;
Use of menopausal therapy or hormonal contraceptives, etc. within the previous 3 months or intent to start during the study period;
BMI \>39 kg/m2;
Vigorous intensity exercise \>2 days per week;
Any current or past history of systemic illness that would interfere with study outcomes such as: diabetes, cancer (other than melanoma), liver, gallbladder disease, peripheral artery disease or thromboembolism, neurological disease, CVD or cerebrovascular disease;
Abnormal thyroid, liver, or kidney function testing during the screening examination or bloodwork;
Plasma glucose \>126 mg/dl under fasting conditions;
Smoking or living with a smoker within the past 12 months;
Current or planned participation in an interventional study during the present study or unwillingness to complete study-related procedures;
Patients who report active acute systemic infection (e.g., flu, common cold, etc), fever (\> 100.0 °F) or feeling ill will be asked to delay vascular testing until they are no longer febrile or ill. Additionally, anyone who has experienced a serious illness (requiring hospitalization) within the last 6 months, had a confirmed positive COVID test and hospitalized, or anyone with a confirmed positive COVID test within the last 6 months will be ineligible to participate (discretion of the study PI and MD).
No use of vitamin/supplements or chronic use of anti-inflammatory medications, or willingness to stop 1 month prior to the vascular visit.
In premenopausal women participating in the intervention:
Contraindications to Degarelix including hypersensitivity to degarelix acetate, extrinsic peptide hormones, mannitol, GnRH, benzyl alcohol (the vehicle for injection of degarelix acetate)
Undiagnosed vaginal bleeding
Osteopenia or osteoporosis (i.e., proximal femur or lumbar spine DXA Z scores \<-1.0)
CES-D score ≥16 (unless clinician follow-up and clinical judgement determine they are eligible (will be noted in study chart)
